Fortitude Family Office’s Alnylam Pharmaceuticals ALNY Stock Holding History

Fortitude Family Office’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$157K	Buy	523 +1	+0.2%	+$302	0.03%	148
2026 Q1	$173K	Buy	522 +5	+1%	+$1.7K	0.04%	129
2025 Q4	$206K	Hold	517	–	–	0.05%	138
2025 Q3	$236K	Hold	517	–	–	0.06%	130
2025 Q2	$169K	Buy	517 +17	+3%	+$4.7K	0.06%	137
2025 Q1	$135K	Buy	+500	New	+$128K	0.05%	130
2024 Q4	–	Sell	-14	Closed	-$3.68K	–	1291
2024 Q3	$3.85K	Buy	+14	New	+$3.65K	﹤0.01%	862

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fortitude Family Office's ALNY Position: Q2 2026 in Review

Fortitude Family Office increased its Alnylam Pharmaceuticals (ALNY) stake by 0.19% in Q2 2026, buying an estimated $302 and bringing the position to 523 shares worth $157K. The position accounts for 0.03% of the portfolio, ranked #148.

Fortitude Family Office first reported a position in ALNY in Q3 2024 and has held it in 7 quarters since. The position peaked at $236K in Q3 2025. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

Fortitude Family Office held 523 shares of Alnylam Pharmaceuticals worth $157K as of Q2 2026.
Fortitude Family Office bought 1 Alnylam Pharmaceuticals share in Q2 2026, an estimated $302.
Alnylam Pharmaceuticals made up 0.03% of Fortitude Family Office's portfolio in Q2 2026, its #148 holding.
Fortitude Family Office first reported a position in Alnylam Pharmaceuticals in Q3 2024 and has held it in 7 quarters since.
Fortitude Family Office's Alnylam Pharmaceuticals position peaked at $236K in Q3 2025.
793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.